Enzyme discovery paves way for greener cancer treatments
Scientists from The University of Manchester have uncovered a more efficient and sustainable way to make peptide-based medicines, showing promising effectiveness in combating cancers.
Peptides are comprised of small chains of amino acids, which are...
Trailblazing scientist is first British winner of Lifetime Achievement Award
British scientist Dame Carol Robinson has received the Lifetime Achievement Award at the European Inventor Award 2024.
The Professor of Chemistry at the University of Oxford is a trailblazer in the field of mass spectrometry...
Scientists create tailored drug for aggressive breast cancer
Scientists have used breast cancer cells’ weakness against themselves by linking a tumour-selective antibody with a cell-killing drug to destroy hard-to-treat tumours.
The research, published in Clinical Cancer Research by a team from King’s College...
Chicken feathers to deliver chemotherapy drugs and repair enzymes
A new method of drug delivery using proline, an amino acid found in chicken feathers and skin tissue, could be used to limit the side effects of chemotherapy and repair important enzymes, new research...
Breakthrough in creating cyclic peptide opens the way for new antibiotics
A discovery by scientists at King’s College London could speed up efforts to produce new antibiotics in the fight against antimicrobial resistance.
In a paper published in the Journal of the American Chemical Society, scientists...
How efficient logistics can change the lives of rare disease patients
Dr. Danial Arkwell, Head of Global Key Accounts, Pharma, at Envirotainer, highlights the vital role of efficient logistics in getting orphan drugs to patients in desperate need.
There are approximately 8,000 rare diseases in the...
Unlocking potential: The impact of CRISPR in organoid research
This exclusive article is by Dr. Ralph Vogelsang, Senior Director of Business Development & Licensing, ERS Genomics.
Conventional drug discovery models, such as animal models or human cell lines, often fail due to their divergence...
New antibiotic ‘evades bacterial resistance’
A promising new weapon has emerged in the fight against drug-resistant bacteria and resultant diseases, writes Rob Mitchum.
The antibiotic cresomycin - described in Science - effectively suppresses pathogenic bacteria that have become resistant to...
Europe’s ‘disappearing’ generic medicines are a growing crisis
Europe’s critical medicine cabinets – in hospitals, pharmacies, and homes – are home to fewer generic medicines. These are the often-cheaper alternatives to brand name medicines, that make up 67%1 of all medicines.
Research from Teva...
Tiny sea microbes could unlock new cures
Off the coast of Spain, studies of the marine microbiome are opening new doors for pharmacology, writes Claudia Alemañy Castilla.
The island of Tabarca, near Alicante, is a tourist magnet. It’s also a working platform...
Breaking new ground in antibiotic research with neutrons
Dr Luke Clifton, Instrument Scientist at ISIS Neutron and Muon Source, explains how neutrons have emerged as a highly effective tool in the fight against AMR.
Antimicrobial resistance (AMR) has been one of the biggest...
£25m funding for future vaccine development
Three ambitious research projects designed to build our understanding of viruses and how the immune system reacts to different challenges will share £25 million in new funding from UK Research and Innovation (UKRI).
Tackling Infections...
Pain killers made from pine trees instead of crude oil
Common drugs such as paracetamol and ibuprofen can be made from a chemical from pine trees instead of crude oil products.
A team of scientists, from the University of Bath’s Department of Chemistry and Institute...
‘World-first’ immunotherapy drug designed by generative AI
British techbio innovator Etcembly has kickstarted the next generation of immunotherapies with a pipeline of best-in-class T cell receptor (TCR) therapeutics designed using generative AI.
The company’s lead therapeutic programme, ETC-101, is the world’s first...
Emerging biotechs jumpstart drug commercialisation via out-licencing – a Deloitte analysis
By Hanno Ronte, life sciences and healthcare partner at Deloitte.
Examining the various go-to-market strategies deployed by emerging biotech companies when launching their first product into Europe reveals how the frequencies of these strategies changed...
Cellular ‘traffic controllers’ caught managing flow of signals from receptors
First time that individual beta-arrestin molecules are directly observed as they control receptor-mediated signals in living cells using advanced microscopy.
New findings could inform the development of better drugs for pain relief,...